HMGCR and breast cancer: Overall, these results encourage additional studies to unravel the role of a still unexplored HMGCR/NANOG partnership in the metabolic reprogramming of tumors and the repurposing of statins as potential adjuvant therapies, which may prevent the generation and maintenance of stem-like, therapy-refractory states in BC.